Highlights
[Nerlynx] has been a little bit slower, it means to have patients who have already been on at least a year of treatment having yet another year of treatment, and does have fairly significant toxicity with diarrhea. So, it’s quite a lot to put a patient through. You should have control of the diarrhea fairly well with loperamide, but it is still a lot of extra treatment when you think you are free of having to come back to the hospital regularly, to then have to take another year of doing so.
…if someone is just on the Herceptin on its own subcutaneously, then you can only give Herceptin subcutaneously, there is no biosimilar subcutaneous treatment at the moment, and it is just so much nicer for the patients, and it is less onerous on the chemotherapy units as well
A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include Enhertu, tucatinib, margetuximab, and the subcutaneous fixed-dose combination of Herceptin and Perjeta.